Spravato outperformed quetiapine on the main endpoint of achieving remission at eight weeks, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with rates of 27.1% and 17.6% ...

J&J’s Janssen unit – which markets Spravato – said at the time it disagreed with the conclusions, which it claimed were “based on inaccurate assumptions…on the established positive ...

As of 10:07:34 AM EDT. Market Open. Loading Chart for STEP ...